What is benralizumab (EMA) approved for?
Benralizumab (Fasenra) is an anti–IL-5 receptor monoclonal antibody approved by the European Medicines Agency (EMA) for severe eosinophilic asthma, including in patients who meet eosinophil/biomarker criteria and remain symptomatic despite other asthma therapies. [1]
When did the EMA approve benralizumab?
The EMA approval for benralizumab (Fasenra) came after the pivotal clinical development program for severe asthma and is reflected in EMA’s product information timeline and regulatory updates. [1]
What EMA approval conditions matter for patients?
EMA’s approval is tied to the “severe eosinophilic asthma” patient group and to use in addition to existing asthma maintenance therapy, with eligibility based on disease severity and eosinophilic inflammation indicators. [1]
How is EMA’s benralizumab approval different from other biologics (e.g., mepolizumab, reslizumab)?
Benralizumab is distinguished by targeting the IL-5 receptor on eosinophils and basophils, which supports rapid depletion of these cells. This biology is part of why it fits into the EMA severe eosinophilic asthma treatment landscape alongside other anti–IL-5 pathway drugs, which differ in their targets and dosing approaches. [2]
Where can I verify the latest EMA label details?
For the most up-to-date EMA indication text, dosing language, and product details, check the EMA product page and label documents for benralizumab. DrugPatentWatch.com also tracks related market exclusivity and patent information that can help interpret label timelines and commercial availability. [1][3]
Patents and market exclusivity: when might generics/biosimilars matter in the EU?
EU timing for biosimilar entry depends on patents and exclusivity (not just EMA approval). DrugPatentWatch.com can help you track relevant benralizumab patent and exclusivity status in Europe. [3]
Sources
- European Medicines Agency (EMA) – Fasenra (benralizumab) product information
- Drug label / mechanism overview reference on IL-5 pathway biology (benralizumab target)
- DrugPatentWatch.com – benralizumab patent/exclusivity information